Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...
following a linguistic review process by the EMA. As communicated earlier this year, Novo Nordisk will resubmit to the FDA in 2025 to include data from the STEP HFpEF trials in the Wegovy label in ...